Cardinal Health (CAH) 2025 Earnings Quality Report

Grade: D — Acquisition Pivot, Negative Equity, Customer Concentration

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2025-08-12, fiscal year ended June 30, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP — Clean opinion (1 Critical Audit Matter)

One-line verdict: Cardinal Health is a pharmaceutical distributor with razor-thin 3.7% gross margins on $222.6B of annual revenue, where a handful of customers drive everything. The 10-K discloses that "CVS Health, accounted for 30 percent of our fiscal 2025 revenue. In the aggregate, our five largest customers, including CVS Health, accounted for 43 percent of our fiscal 2025 revenue" — a degree of customer concentration rare in large-cap healthcare. Revenue declined 1.9% to $222.58B following the expiration of the OptumRx distribution contract in the prior year, but the company executed a major strategic pivot: $5.25B of 2025 acquisition spending to buy Integrated Oncology Network ($1.1B, Dec 2024), GI Alliance ($2.8B, 73% ownership, Jan 2025), Advanced Diabetes Supply Group ($1.1B, Apr 2025), and Urology America ($360M, May 2025), all at-home or physician practice management services organizations that carry much higher margins than distribution. Goodwill surged 96% in a single year from $4.73B to $9.27B (E2 watch). Two other flags: cash of $3.87B covers 45% of $8.53B debt (C4 fail), and other soft assets grew 36.2% vs revenue growth of -1.9% (D3 watch). Stockholders' equity is negative $2.78B — the second company in this batch with negative equity after ABBV, caused by years of share buybacks exceeding earnings. The Altman Z-Score of -0.02 is in distress territory for the same mechanical reason. EY's Critical Audit Matter is on goodwill valuation for the newly-acquired Navista/ION and Cardinal Health at-Home Solutions reporting units — directly targeting the just-completed acquisitions.

Business: Two Segments, Distribution Plus MSO Pivot

Per Item 1 of the 10-K: "We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions ('Pharma') segment and Global Medical Products and Distribution ('GMPD') segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics."

The Pharma segment is the dominant business: "Our Pharma segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products."

Customer Concentration — The Central Risk

Per Item 1: "Our largest customer, CVS Health, accounted for 30 percent of our fiscal 2025 revenue. In the aggregate, our five largest customers, including CVS Health, accounted for 43 percent of our fiscal 2025 revenue."

30% from a single customer is the most concentrated revenue structure in this batch of 10 companies. CAH also discloses GPO dependence: "We have agreements with group purchasing organizations ('GPOs') that act as agents to negotiate vendor contracts on behalf of their members. Our two largest GPO relationships in terms of revenue are with Vizient, Inc. and Premier, Inc."

The Acquisitions Pivot

Per the MD&A, fiscal 2025 included four meaningful acquisitions:

Total acquisition spending: $5.25B+ in fiscal 2025. This is CAH's largest M&A year in more than a decade. The common thread is specialty care services — Cardinal is pivoting from low-margin pure distribution toward physician practice management, which carries significantly higher EBITDA margins.

Profitability: Thin Margins on Massive Volume

Per the consolidated statements of operations:

The 2025 revenue decline of 1.9% is explained by the expiration of the OptumRx distribution contract in fiscal 2024, which removed approximately $30-40B of low-margin revenue from the run-rate. This is why gross margin improved and EBITDA grew 58% year-over-year even as revenue fell.

Per the MD&A: the new acquisitions (ION, GIA, ADS) contributed high-margin revenue and profit to fiscal 2025 results, particularly in Q4 after GIA closed in January 2025.

Interest expense grew from $51M to $215M year-over-year — a 4x increase reflecting the debt raise to fund the acquisitions.

Cash Flow: Still Positive, But Down

Per the consolidated statements of cash flows:

The CFFO decline from $3.76B to $2.40B (-36%) is significant. The C1 and C2 checks still pass because net income itself is much lower than CFFO in absolute terms — distribution businesses have large non-cash working capital swings — but the trend is downward.

The -$5.25B business acquisition outflow is the dominant cash event of 2025. Combined with the $2.40B CFFO and ~$3.2B of new debt issuance, CAH financed the acquisitions with roughly half debt, half cash.

Balance Sheet: Negative Equity, Soaring Goodwill

Per the balance sheet:

Negative equity. Cardinal Health has been carrying negative stockholders' equity since 2022, a result of years of share repurchases at prices above book value. In fiscal 2025, equity improved from -$3.21B to -$2.78B as retained earnings recovered.

C4 FAIL: Cash of $3.87B covers 45% of debt of $8.53B. Debt jumped 67% in a single year (from $5.09B to $8.53B) to fund the acquisitions. A year ago, CAH's cash actually exceeded its total debt (101% ratio). The transformation of the balance sheet in a single year is notable.

D1 PASS (mechanically): Goodwill + intangibles of $12.2B against negative equity produces a negative percentage that the engine codes as "manageable." This is misleading in direction. The actual meaning is that the intangibles exceed equity by a substantial amount.

E2 WATCH: Goodwill + intangibles jumped 89% YoY. This directly reflects the $5.25B in new acquisitions. The fiscal 2026 purchase price allocations will finalize in coming quarters.

D3 WATCH: Other soft assets grew 36.2% vs revenue growth of -1.9%. This is consistent with the acquisition-driven asset growth — new physician practice management goodwill and customer relationships come in as soft assets, regardless of revenue contribution in the partial year.

The 18-Point Screening

Note on A2: the engine's simple check passes because revenue declined overall. But AR grew 9.6% even as revenue fell — DSO climbed from 20 to 22 days. In a distribution business with traditionally tight working capital, this is a modest warning.

Beneish M-Score components: DSRI 1.117, GMI 0.891 (gross margin improved — good), AQI 1.531 (asset quality index sharply elevated), SGI 0.981 (declining), DEPI 1.012, SGAI 1.097, TATA -0.0157, LVGI 0.988.

The AQI of 1.531 is the M-Score's most concerning component. AQI measures the ratio of non-current assets other than PP&E to total assets. A big jump typically signals capitalization of costs that should be expensed, or aggressive goodwill. In CAH's case, the elevated AQI is mechanically explained by the $4.5B of new goodwill from the four fiscal-2025 acquisitions — goodwill is a non-current asset other than PP&E. The M-Score of -2.32 is below the -2.22 threshold, but only barely. A further elevation of AQI (more goodwill from additional acquisitions) could push the M-Score into the grey zone.

Altman Z-Score -0.02: distress zone. Components: X1 working capital/assets 0.01, X2 retained earnings/assets -0.07 (negative), X3 EBIT/assets 0.05, X4 equity/liabilities -0.05 (negative). Like ABBV, the Z-Score is mechanically driven into distress by the negative equity. Interest coverage of EBIT/Interest = $2.9B/$215M = 13.5x is healthy; Debt/EBITDA of 2.7x is normal. This is a capital-structure-driven number, not an operating distress signal.

Key Risks from the 10-K (Item 1A)

1. Customer Concentration — CVS Health at 30%

Per Item 1: "Our largest customer, CVS Health, accounted for 30 percent of our fiscal 2025 revenue. In the aggregate, our five largest customers, including CVS Health, accounted for 43 percent of our fiscal 2025 revenue."

A single customer at 30% of $222.6B is approximately $66.8B of annual revenue dependent on a single contract relationship. The OptumRx contract expiration in fiscal 2024 demonstrated what customer loss looks like — it removed tens of billions of dollars of revenue. A similar event with CVS Health would be existential.

2. Pharmaceutical Distribution Margin Pressure

Pharmaceutical distribution is a volume business with 3-5% gross margins. Any pricing pressure from manufacturers or customers compresses the margin. The 10-K discusses pricing pressure throughout Item 1A.

3. Opioid Litigation Overhang

Cardinal Health remains party to ongoing opioid litigation settlements. The 10-K continues to disclose opioid-related reserves and litigation. While the 2022 $6B+ global settlement resolved most state-level claims, remaining municipal and tribal claims persist.

4. Acquisition Integration Risk

Four major acquisitions completed within seven months of each other (ION Dec 2024, GIA Jan 2025, ADS Apr 2025, Urology America May 2025) creates substantial integration risk. Cardinal's operational track record in non-distribution businesses is mixed — Cordis (medical devices) was divested in 2021 after integration struggles. The new MSO acquisitions operate in a different business model (risk-sharing, population health) than core distribution.

5. Interest Expense Escalation

Interest expense jumped from $51M to $215M in a single year (a 321% increase). The new debt raised to fund the acquisitions carries higher interest rates than pre-pandemic debt. Further refinancing at prevailing rates could pressure net income.

Auditor's Critical Audit Matter: Goodwill on Just-Acquired Businesses

Ernst & Young has audited Cardinal Health since 2002 — 23 years. The 2025 audit identified one Critical Audit Matter: Valuation of Goodwill.

Per the audit report: "The Company performed quantitative assessments of goodwill for the Company's Navista & ION and Cardinal Health at-Home Solutions reporting units during fiscal year 2025... During fiscal 2025, there was no impairment recognized related to Navista & ION or Cardinal Health at-Home Solutions."

EY explains the judgment: "Auditing management's goodwill impairment test for Navista & ION and Cardinal Health at-Home Solutions was challenging because there is significant judgement required in determining the fair values of the reporting units. In particular, the fair value estimates were sensitive to significant judgmental assumptions including the revenue growth rate; gross margin; distribution, selling, general and administrative expenses, and company-specific risk premium, which are affected by expectations about future market or economic conditions."

Why this matters: Navista (the BD oncology network business) and ION (acquired Dec 2024) are the centerpieces of Cardinal's push into oncology practice management. EY's CAM signals that the fair value of these acquired businesses is close enough to carrying value that the impairment test is a judgment call. Any deterioration in physician recruitment, reimbursement rates, or integration execution could trigger a write-down on goodwill that just got added to the balance sheet.

The at-Home Solutions reporting unit (including the new ADS acquisition) is in the same position — fresh acquisition goodwill with high sensitivity to forecast assumptions.

Key Financial Trends (4-Year)

Summary

Grade: D. One red flag, two watch items, and a structurally concerning combination of customer concentration, negative equity, and just-acquired goodwill.

Cardinal Health's 2025 is the story of a distributor becoming a hybrid distributor + physician practice manager. Revenue is down 1.9% but net income is up 83% because the mix is shifting toward higher-margin specialty services. Gross margin improved from 3.3% to 3.7% (a 40 bp improvement on $222B of revenue is meaningful). EBITDA grew from $1.96B to $3.11B. Free cash flow of $1.85B still covers the $494M dividend with substantial margin.

The 18-check screen returns three concerns:

Three contextual facts amplify these concerns:

Customer concentration. CVS Health is 30% of revenue. Five customers are 43%. The 10-K's Item 1 disclosure is blunt about this. Any change in the CVS relationship would be the single largest risk to the business.

Negative equity at -$2.78B. Like ABBV, Cardinal has negative stockholders' equity from years of share buybacks exceeding earnings. The Altman Z-Score of -0.02 is mechanically in the "distress" zone for this reason, not because of operating weakness. Interest coverage is 13.5x and Debt/EBITDA is 2.7x — both healthy.

Acquisition integration timing. Four acquisitions closed within seven months (December 2024 to May 2025). The fiscal 2025 results include only partial-year contributions. Fiscal 2026 will be the true test of whether the ION + GIA + ADS + Urology America combination performs as Cardinal underwrote. Ernst & Young's Critical Audit Matter flags the goodwill on Navista & ION and Cardinal Health at-Home Solutions as "sensitive to significant judgmental assumptions including the revenue growth rate; gross margin... and company-specific risk premium, which are affected by expectations about future market or economic conditions."

The Beneish M-Score of -2.32 is below the -2.22 threshold, but closer to it than any other company in this batch. The elevated AQI of 1.531 directly reflects the goodwill surge. An additional large acquisition could push the M-Score into the grey zone.

Read the 10-K. Read the customer concentration disclosure in Item 1. Read Notes 1 and 5 on goodwill valuation. Read the Navista/ION business combination note. Then decide whether the pivot is a coherent strategy or a leveraged response to distribution margin pressure.

**Disclaimer**: This report is based on Cardinal Health's fiscal year 2025 10-K filed with the SEC on August 12, 2025. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade D means material concerns were identified that warrant investigation.